MoonLake Immunotherapeutics (MLTX)vsModerna Inc (MRNA)
MLTX
MoonLake Immunotherapeutics
$12.87
-4.74%
HEALTHCARE · Cap: $919.15M
MRNA
Moderna Inc
$231.35
-6.97%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
MLTX leads profitability with a 0.0% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).
MLTX
Avoid28
out of 100
Grade: F
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLTX.
Margin of Safety
+73.1%
Fair Value
$150.76
Current Price
$231.35
$80.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 13.7x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MLTX
The strongest argument for MLTX centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
MLTX profiles as a value stock while MRNA is a growth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.17 — expect wider price swings.
MRNA is growing revenue faster at 29.2% — sustainability is the question.
MLTX generates stronger free cash flow (-56M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (31/100 vs 28/100) and 29.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery technology. The company is actively developing its lead candidate, a groundbreaking interleukin-17 inhibitor, currently undergoing multiple phases of clinical trials, which has the potential to transform treatment paradigms and improve patient outcomes. With a robust research pipeline and strategic collaborations, MoonLake Immunotherapeutics is poised to meet significant unmet medical needs in the immunotherapy sector, presenting substantial opportunities for institutional investors seeking exposure to the evolving biotech landscape.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?